TESTOSTERONE CYPIONATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for testosterone cypionate and what is the scope of freedom to operate?
Testosterone cypionate
is the generic ingredient in two branded drugs marketed by Pfizer, Am Regent, Cipla, Eugia Pharma, Hikma, Hikma Farmaceutica, Padagis Us, Rising, Sandoz, Sun Pharm Inds Ltd, Watson Labs, Watson Pharms Inc, Wilshire Pharms Inc, Xiromed, and Azurity, and is included in sixteen NDAs. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.There are ten drug master file entries for testosterone cypionate. Twenty suppliers are listed for this compound.
Summary for TESTOSTERONE CYPIONATE
US Patents: | 2 |
Tradenames: | 2 |
Applicants: | 15 |
NDAs: | 16 |
Drug Master File Entries: | 10 |
Finished Product Suppliers / Packagers: | 20 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Clinical Trials: | 30 |
Patent Applications: | 4,770 |
Drug Prices: | Drug price trends for TESTOSTERONE CYPIONATE |
What excipients (inactive ingredients) are in TESTOSTERONE CYPIONATE? | TESTOSTERONE CYPIONATE excipients list |
DailyMed Link: | TESTOSTERONE CYPIONATE at DailyMed |
Recent Clinical Trials for TESTOSTERONE CYPIONATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
Yale University | Phase 2 |
Dendreon | Phase 2 |
Pharmacology for TESTOSTERONE CYPIONATE
Drug Class | Androgen |
Mechanism of Action | Androgen Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for TESTOSTERONE CYPIONATE
US Patents and Regulatory Information for TESTOSTERONE CYPIONATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma Farmaceutica | TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 091244-001 | May 1, 2012 | AO | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sun Pharm Inds Ltd | TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 201720-002 | Jun 3, 2013 | AO | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Watson Labs | TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 084401-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Am Regent | TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 207742-001 | Jun 16, 2017 | AO | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Sun Pharm Inds Ltd | TESTOSTERONE CYPIONATE | testosterone cypionate | INJECTABLE;INJECTION | 201720-001 | Jun 3, 2013 | AO | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.